NDAORALTABLETPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
JAYPIRCA (pirtobrutinib) by Eli Lilly and Company is bruton's tyrosine kinase inhibitors [moa]. First approved in 2023.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JAYPIRCA (pirtobrutinib) is an oral Bruton's Tyrosine Kinase (BTK) inhibitor approved in January 2023 for hematologic malignancies, particularly chronic lymphocytic leukemia and other B-cell lymphomas. It works by selectively inhibiting BTK, a key enzyme in B-cell receptor signaling pathways critical to cancer cell survival and proliferation.
$0.049BPart D
Peak15.2 years to LOEPeak-stage oral oncology product with strong patent protection through 2041; expect stable, specialized commercial infrastructure focused on hematology-oncology channels.
Mechanism of Action
Bruton's Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Started Jun 2026
620 enrolled
B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Started Jun 2026
25 enrolled
Waldenstrom Macroglobulinemia
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Started Apr 2026
306 enrolled
CLL / SLLCLL (Chronic Lymphocytic Leukemia)CLL, Refractory+5 more
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Started Mar 2026
150 enrolled
Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
Started Feb 2026
56 enrolled
Mantle Cell Lymphoma
Worked on JAYPIRCA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.